Drug Trial Radar · NCT00199420
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
580
Actual
Start
Jul 2004
Primary completion
Nov 2005
Study completion Dec 2005
Sponsor
- Lead sponsor
- Kyowa Kirin, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
Conditions
- Parkinson's Disease
Interventions
Istradefylline (KW-6002)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To establish the efficacy of 10, 20 and 40 mg/d istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Kyowa Pharmaceutical Inc.
Princeton, New Jersey
Kyowa Pharmaceutical
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.